Clinical Use of Blood Biomarkers in the Era of Disease Modifying Treatments for Early Symptomatic Alzheimer’s Disease

In this webinar, Suzanne E. Schindler, MD, PhD, Associate Professor of Neurology, Washington University will review the types of AD biomarker tests that are clinically available, including cerebrospinal fluid (CSF) biomarkers, amyloid positron emission tomography (PET) and AD blood tests.

Viewers will gain insights into:

  • The challenges in clinical practice that limit the use of CSF fluid biomarkers and amyloid PET for optimal patient care

  • The practical benefits of blood tests for patients with signs or symptoms of cognitive impairment who are undergoing evaluation for AD

  • The variability in the diagnostic performance of AD blood tests and how performance affects the clinical use of tests

  • How certain AD blood tests have comparable accuracy to FDA-cleared CSF tests based on observed data from rigorous clinical studies


Dr. Suzanne Schindler is a Clinical Neurologist and Neuroscientist focused on improving the diagnosis and treatment of Alzheimer’s disease. She completed the MD/PhD program at Washington University, where she studied the basic biology of apolipoprotein E, a key protein implicated in Alzheimer’s disease pathogenesis. Dr. Schindler then trained in clinical neurology at Washington University and completed a fellowship in dementia.

Currently, Dr. Schindler sees patients with memory concerns and coordinates biomarker testing for the Washington University Memory Diagnostic Center. She leads the Fluid Biomarker Core for the Knight Alzheimer Disease Research Center, which includes coordinating numerous collaborations. She received a large R01 to evaluate novel plasma biomarkers of Alzheimer’s disease. She is very interested in translating research findings into clinical practice. Further, she has a particular focus on understanding and reducing disparities in healthcare.

(Dr. Schindler did not receive compensation from C2N Diagnostics and will review multiple high-accuracy AD blood tests.)


Interested in learning more? Leave us a note.

Next
Next

Goldman Sachs Alzheimer’s Disease Day — Infrastructure considerations: Outlook for blood-based testing